JK-1201I + temozolomide

**JK-1201I + temozolomide** is a combination therapy under investigation, comprised of JK-1201I, a novel pegylated (polyethylene glycol-modified) irinotecan derivative, and **temozolomide**, an oral alkylating agent. JK-1201I is engineered for prolonged circulation and enhanced tolerability compared to conventional irinotecan, functioning primarily as a topoisomerase I inhibitor, which interferes with DNA replication in cancer cells. Temozolomide induces DNA methylation damage, leading to cytotoxicity in dividing tumor cells. This combination is being evaluated for the treatment of newly diagnosed glioblastoma multiforme (GBM) and potentially other cancers, with early-phase clinical studies focused on safety, tolerability, efficacy, and pharmacokinetics[3][5][6][7].

Other names

polyethylene glycol irinotecan + temozolomide